Showing results (251-260 of 793) with videos related to
Sort By:
Pageof 80
Transfusion|February 22, 2011
A randomized clinical trial comparing granulocyte-colony-stimulating factor administration sites for mobilization of peripheral blood stem cells for patients with hematologic malignancies undergoing autologous stem cell transplantationHeather Renfroe, Mike Arnold, Louette Vaughn, et al.Expert Review of Anticancer Therapy|June 9, 2015
Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myelomaPaul G Richardson, Jacob P Laubach, Sagar Lonial, et al.Blood Cancer Journal|September 13, 2024
Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patientsNisha S Joseph, Jonathan L Kaufman, Vilas A Gupta, et al.Transfusion|March 27, 2007
Optimizing the timing of chemotherapy for mobilizing autologous blood hematopoietic progenitor cellsMichelle L Hicks, Sagar Lonial, Amelia Langston, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2012
Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myelomaSagar Lonial, Ravi Vij, Jean-Luc Harousseau, et al.Blood|August 17, 2013
PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myelomaPaul G Richardson, Robert L Schlossman, Melissa Alsina, et al.Clinical Lymphoma, Myeloma & Leukemia|April 26, 2025
Treatment Patterns and Clinical Outcomes of Patients With Systemic Light Chain Amyloidosis in the United States: Evidence From Real-World Clinical PracticeSophia S Li, Anita D'Souza, Suzanne Lentzsch, et al.Plos One|November 28, 2012
Anti-myeloma activity of Akt inhibition is linked to the activation status of PI3K/Akt and MEK/ERK pathwayVijay Ramakrishnan, Teresa Kimlinger, Jessica Haug, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2010
Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's diseaseFrits van Rhee, Luis Fayad, Peter Voorhees, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2020
Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple MyelomaNisha S Joseph, Jonathan L Kaufman, Madhav V Dhodapkar, et al.Pageof 80